We are all in this together. We are currently recruiting
for two COVID-19 studies.

COVID CSSC-001 Study:

This study is for people at risk of exposure to COVID-19, such as hospital personnel (clinical staff, environmental services, etc.) or anyone who is caring for someone with COVID-19.
This study will test whether an infusion of plasma containing antibodies from persons who have recovered from COVID-19 can prevent others from getting COVID-19. Antibodies are part of the body's immune system. Plasma is the liquid portion of the blood.

Getting plasma with COVID antibodies may help your body to develop its own antibodies, protecting you from COVID infection.

Can I Join?

You may be able to join if you:

  • Are 18 years of age or older
  • Are at high risk for COVID exposure as a healthcare worker OR because you care for a COVID patient in your household

What’s involved?

  • Up to 7 study visits (physical exam, blood tests, medical history, one plasma infusion)

COVID CSSC-004 Study:

This study is for persons who have had any COVID symptoms within the past 6 days or less (cough shortness of breath, fever, chills, muscle pain, headache, sore throat, new loss of taste of smell, neurological changes, or new skin rash).

This study will test whether a transfusion of plasma that has antibodies from persons who have recovered from COVID-19 is a good treatment for patients with early COVID-19 illness.

Can I Join?

You may be able to join if you:

  • Are 18 years of age or older
  • Have had any COVID symptoms within the past 6 days or less (cough shortness of breath, fever, chills, muscle pain, headache, sore throat, new loss of taste of smell, neurological changes, or new skin rash).

What’s involved?

  • Up to 5 study visits (physical exam, blood tests, medical history, one plasma infusion)
  • Daily symptom log

Sign Up

As research opportunities arise, we will contact people who have expressed interest if they match our current research criteria. We sincerely thank you for your interest in supporting the effort to fight this illness. Regards, COVID CSSC-001 & COVID CSSC-004 Research Team.